Sign In
Buy MNKD
$3.36
-0.0700 (-2.04%)
At Close: Jun 03, 2026
MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March 19-22
MannKind Q4 Review: Solid Financials, But Tyvaso DPI's Market Share In Question
10:32am, Thursday, 27'th Feb 2025
MannKind's stock has fluctuated due to Tyvaso DPI's Q4 underperformance and competitive pressures, but it remains a key revenue driver for future profitability and R&D funding. Tyvaso DPI's potential
MannKind Corporation (MNKD) Q4 2024 Earnings Call Transcript
09:09pm, Wednesday, 26'th Feb 2025
MannKind Corporation (NASDAQ:MNKD ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Corporate Participants Michael Castagna - Chief Executive Officer Chris Prentiss - Chief Financial Off
Compared to Estimates, MannKind (MNKD) Q4 Earnings: A Look at Key Metrics
08:31pm, Wednesday, 26'th Feb 2025
Although the revenue and EPS for MannKind (MNKD) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Str
MannKind (MNKD) Q4 Earnings Meet Estimates
07:15pm, Wednesday, 26'th Feb 2025
MannKind (MNKD) came out with quarterly earnings of $0.03 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.02 per share a year ago.
MannKind Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
04:05pm, Wednesday, 26'th Feb 2025
2024 revenues of $286M, +43% v. 2023; 4Q 2024 revenues of $77M, +31% v.
Unveiling MannKind (MNKD) Q4 Outlook: Wall Street Estimates for Key Metrics
10:21am, Monday, 24'th Feb 2025
Get a deeper insight into the potential performance of MannKind (MNKD) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for
MannKind Corporation to Hold 2024 Fourth Quarter and Full Year Financial Results Conference Call on February 26, 2025
04:05pm, Wednesday, 19'th Feb 2025
DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
MoneyShow's Best Investment Ideas For 2025: Part 8
09:20am, Monday, 03'rd Feb 2025
MoneyShow presents top investment ideas for 2025 from their contributors. This year's edition presents a broad mix of theme-based stock picks, momentum-driven high-flyers and beaten-up stocks with tur
MannKind Expands Executive Leadership Team
04:30pm, Monday, 06'th Jan 2025
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focusing on the development and commercialization of innovative inhaled th
MannKind Corporation: A Speculative Buy On IPF And Diabetes Markets
07:16am, Tuesday, 17'th Dec 2024
MannKind Corporation is a biopharmaceutical company focused on inhaled therapies for endocrine and orphan lung diseases. MNKD's revenue growth is driven by Tyvaso DPI royalties and Afrezza expansion,
MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®)
06:05am, Monday, 16'th Dec 2024
Company plans to meet with FDA regarding potential sNDA submission in 1H 2025 Call planned today at 8:30 a.m. (ET) to discuss company's diabetes program progression DANBURY, Conn.
CDSCO Approves Afrezza® (insulin human) Inhalation Powder in India
06:00am, Wednesday, 11'th Dec 2024
India has the 2 nd highest burden of diabetes worldwide CDSCO decision follows existing approvals in the U.S.A. and Brazil MannKind expects to ship product for Cipla Ltd.
MannKind Corporation (MNKD) Q3 2024 Earnings Conference Call Transcript
08:30pm, Thursday, 07'th Nov 2024
MannKind Corporation (NASDAQ:MNKD ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Michael Castagna - CEO Chris Prentiss - CFO Conference Call Participants Andreas A
MannKind (MNKD) Reports Q3 Earnings: What Key Metrics Have to Say
08:01pm, Thursday, 07'th Nov 2024
The headline numbers for MannKind (MNKD) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street est
